par Paul Saltet | Déc 10, 2024 | Uncategorized
HEPHAISTOS-Pharma has the honor to be a winner of a Golden Ticket from Amgen France x BioLabs Hôtel-Dieu in Paris. We have won one year of free residency at BioLabs Hôtel-Dieu and personalized mentorship from Amgen experts to accelerate the development of our...
par Paul Saltet | Déc 5, 2024 | Uncategorized
HEPHAISTOS-Pharma was laureate of the Hack4Hope, the hackathon against pediatric cancer following a great day of speed dating with pharmas, patients’ associations and experts in childhood cancer The jury was composed of experts in Oncology and Childhood cancer from...
par Paul Saltet | Mai 16, 2024 | Uncategorized
HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led by Elaia with xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business...
par Paul Saltet | Mar 14, 2024 | Uncategorized
Our CEO, Frederic CAROFF will be attending BIO-Europe Spring 2024 in Barcelona from March 18th to 20th. He will meet series A investors interested in Oncology biotech companies developing game-changing immunotherapy platform. He will also discuss with Pharmaceutical...
par Paul Saltet | Jan 23, 2024 | Uncategorized
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic. ONCO-Boost is a novel class of TLR4...
